Short Interest in Lipocine Inc. (NASDAQ:LPCN) Decreases By 41.2%

Lipocine Inc. (NASDAQ:LPCN) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 102,133 shares, a decline of 41.2% from the April 30th total of 173,716 shares. Based on an average daily trading volume, of 103,762 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.3% of the company’s shares are short sold.

Insider Buying and Selling at Lipocine

In other news, CEO Mahesh V. Patel bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were bought at an average cost of $2.03 per share, with a total value of $50,750.00. Following the completion of the purchase, the chief executive officer directly owned 160,679 shares in the company, valued at $326,178.37. This represents a 18.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director John W. Higuchi bought 123,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average cost of $2.05 per share, for a total transaction of $252,150.00. Following the completion of the purchase, the director owned 163,797 shares of the company’s stock, valued at $335,783.85. This trade represents a 301.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 213,000 shares of company stock worth $434,600. 6.35% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LPCN. Citadel Advisors LLC bought a new position in shares of Lipocine in the 3rd quarter worth about $41,000. Jane Street Group LLC bought a new position in shares of Lipocine in the 4th quarter worth about $85,000. Dimensional Fund Advisors LP increased its stake in shares of Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after acquiring an additional 6,982 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Lipocine in the 1st quarter worth about $185,000. Finally, Renaissance Technologies LLC boosted its stake in Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares in the last quarter. 9.11% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Wall Street Zen cut shares of Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $15.00.

Lipocine Price Performance

Shares of Lipocine stock opened at $2.28 on Tuesday. The company has a 50-day moving average of $3.25 and a 200 day moving average of $5.62. The firm has a market cap of $18.79 million, a price-to-earnings ratio of -1.22 and a beta of 0.48. Lipocine has a 1 year low of $1.81 and a 1 year high of $12.37.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. On average, equities analysts anticipate that Lipocine will post -1.91 EPS for the current year.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.